Core Viewpoint - The Hong Kong Stock Exchange reported that during the week from October 13 to October 19, 9 companies submitted listing applications, 5 companies passed the hearing, 4 companies launched their IPOs, and 2 new stocks were listed [1]. Group 1: Companies Submitted Listing Applications - Hantian Technology (Xiamen) Co., Ltd. is a leader in the global silicon carbide (SiC) epitaxy industry, focusing on the R&D, mass production, and sales of SiC epitaxy chips, with a projected market share of over 30% in 2024 [2]. - Impression Co., Ltd. is a state-owned cultural tourism service enterprise, ranking eighth in China's cultural tourism performance market in 2024, with revenues of approximately 63.04 million yuan in 2022 [3]. - Guangzhou Yujian Noodle Restaurant Co., Ltd. is the fourth largest operator of Chinese noodle restaurants in China, with a market share of 0.5% in 2024 [4]. - Baishan Cloud Holdings Ltd. is the second largest independent edge cloud service provider in China, with a market share of approximately 2.0% in 2024 [5][6]. - Shouchuang Securities Co., Ltd. is a financial service provider with a strong asset management capability, ranking fifth in revenue growth among 42 A-share listed securities companies from 2022 to 2024 [7]. - Chongqing Qianli Technology Co., Ltd. focuses on AI and mobility solutions, with stable growth in automotive products [8]. - Nanjing Qingtian All Tax Information Technology Co., Ltd. is a leading digital service provider for cross-border enterprises, ranking first in the smart tax solution market in China with a market share of 1.7% in 2024 [9]. - Lakala Payment Co., Ltd. is a leading digital payment provider in Asia, with a market share of 9.4% in 2024 [10]. - Sichuan Xin Hehua Traditional Chinese Medicine Co., Ltd. is one of the largest suppliers of traditional Chinese medicine products in China, ranking second in the market with a 0.4% market share in 2024 [12]. Group 2: Companies Passed Hearing - Seres Group Co., Ltd. focuses on the research, manufacturing, and sales of new energy vehicles, achieving revenues of approximately 340.56 billion yuan in 2022 [13]. - Minglue Technology is a leading data intelligence application software company in China, with revenues of approximately 12.69 billion yuan in 2022 [14]. - Pony AI Inc. specializes in autonomous driving services, with a total operational area exceeding 2000 square kilometers [15]. - Ningbo Joyson Electronic Corp. is a global leader in smart automotive technology solutions, ranking second in China and fourth globally in smart cockpit domain control systems [16][17]. - WeRide Inc. is a pioneer in L4 autonomous driving, with operations in over 30 cities across 11 countries [18]. Group 3: Companies Launched IPOs - Yunji Technology launched its IPO with a subscription that was oversubscribed by 5677 times, raising approximately 189.1 billion HKD [19]. - Haixi New Drug's IPO was delayed for regulatory approval, with a price range of 69.88-86.40 HKD per share [20]. - Jushuitan's IPO was set at 30.60 HKD per share, with a total of 681.66 million shares offered [21]. - Guanghetong's IPO was priced between 19.88-21.5 HKD per share, with a total of approximately 135 million shares offered [21]. Group 4: Newly Listed Stocks - Xuan Bamboo Biotechnology was listed on October 15, 2025, with a closing price of 26.30 HKD per share, reflecting a gain of 126.72% [22]. - Yunji was listed on October 16, 2025, with a closing price of 120.5 HKD per share, reflecting a gain of 26.05% [24].

受益于新能源汽车、光伏储能、数据中心乃至于AR眼镜等终端行业的增长，近年来碳化硅市场急速扩 容。据了解，由于具有宽禁带、高热导率、高耐击穿场强、高电子饱和速率等突出优点，碳化硅能够在 广泛的温度范围内实现高效、高速且稳定的电力控制与处理，被视为是支撑多种电力系统利用电力 的"智能心脏"。数据显示，2024年全球碳化硅功率半导体器件行业的销售额为26亿美元，2020-2024年 间的复合年增长率高达45.4%；至2029年，市场容量有望进一步放大至136亿元。相对应的，全球碳化 硅功率半导体器件在全球功率半导体市场中的渗透率亦将同步从2024年的4.9%提升至2029年的17.1%。 整个产业链快速起量，中间环节的"含金量"自然也是水涨船高。就拿碳化硅外延晶片来说，作为连接创 新原材料与高性能器件的基石，碳化硅外延晶片的质量至关重要且外延层制造的价值约占整个碳化硅功 率器件价值链的25%。2024年，全球碳化硅外延晶片市场的销售额为12亿美元，预计至2029年将以 38.2%的复合年增长率增加至58亿美元。 收入增长态势未能延续之外，另一个值得关注的特征则是瀚天天成内销比重正重回高位。2022年至2025 年前 ...

受益于新能源汽车、光伏储能、数据中心乃至于AR眼镜等终端行业的增长，近年来碳化硅市场急速扩 容。据了解，由于具有宽禁带、高热导率、高耐击穿场强、高电子饱和速率等突出优点，碳化硅能够在 广泛的温度范围内实现高效、高速且稳定的电力控制与处理，被视为是支撑多种电力系统利用电力 的"智能心脏"。数据显示，2024年全球碳化硅功率半导体器件行业的销售额为26亿美元，2020-2024年 间的复合年增长率高达45.4%；至2029年，市场容量有望进一步放大至136亿元。相对应的，全球碳化 硅功率半导体器件在全球功率半导体市场中的渗透率亦将同步从2024年的4.9%提升至2029年的17.1%。 整个产业链快速起量，中间环节的"含金量"自然也是水涨船高。就拿碳化硅外延晶片来说，作为连接创 新原材料与高性能器件的基石，碳化硅外延晶片的质量至关重要且外延层制造的价值约占整个碳化硅功 率器件价值链的25%。2024年，全球碳化硅外延晶片市场的销售额为12亿美元，预计至2029年将以 38.2%的复合年增长率增加至58亿美元。 乘上行业高速发展东风，全球碳化硅外延行业领导者瀚天天成电子科技（厦门）股份有限公司（以下简 称"瀚天天成 ...

Core Viewpoint - Hantian Technology has submitted a listing application to the Hong Kong Stock Exchange, with CICC as the sole sponsor [1] Group 1: Company Overview - Hantian Technology is the world's first mass producer of 8-inch silicon carbide (SiC) epitaxial chips and the first in China to achieve mass supply of 3, 4, 6, and 8-inch SiC epitaxial chips [1] - As of 2023, Hantian Technology is the largest SiC epitaxial supplier globally by sales volume, with a market share exceeding 30% projected for 2024 [1] - The company has sold over 164,000 SiC epitaxial chips cumulatively by 2024, with total deliveries exceeding 500,000 chips during the historical performance period [1] Group 2: Industry Leadership - Hantian Technology leads the global SiC epitaxial industry and has established the first and only SEMI industry standard for SiC epitaxy [1] - The company's customer base includes 4 out of the top 5 global SiC power device giants and 7 out of the top 10 power device companies [1] Group 3: Application Areas - SiC epitaxial chips are applicable in a wide range of sectors, including electric vehicles, charging infrastructure, renewable energy, energy storage, home appliances, AI computing, data centers, smart grids, and eVTOL [1]

据港交所10月14日披露，瀚天天成电子科技(厦门)股份有限公司(以下简称：瀚天天成)再次向港交所提交上市申请书，中金公司（601995）为独家保荐人。 该公司曾于4月8日向港交所递表。招股书提到，瀚天天成是全球率先实现8英吋碳化硅外延芯片大批量外供的生产商，也是中国首家实现商业化3英吋、4英 吋、6英吋和8英吋碳化硅外延芯片批量供应的生产商。 | 篇纂]的[編纂]數目 : [編纂]股H股(視乎[編纂] | 行使情況而定) | | | | | | --- | --- | --- | --- | --- | --- | | [編纂]數目 | . . | 「編纂】股H股(可予重新分配) | [編纂]數目 | . . | 「編纂」股H股(可予重新分配及 | | 視乎[編纂]行使與否而定） | .. | 每股H股[編纂]港元,另加1.0%經紀 | 最高[編纂] | | | | 佣金、0.0027％證監會交易徵費、 | 0.00015%會財局交易徵費及 | | | | | | 0.00565％聯交所交易費(須於 | 「編纂]時以港元繳足, | | | | | | 多繳股款可予退還) | . | 面值 | 每股H股人民幣1 ...

Group 1 - The core point of the article is that Hantian Technology (Xiamen) Co., Ltd. has seen its Hong Kong IPO application expire after six months, with CICC serving as the sole sponsor during the application process [1] - Hantian Technology is recognized as a leader and innovator in the global silicon carbide (SiC) epitaxy industry [2] - According to a report by Zhi Shi Consulting, Hantian Technology is the largest supplier of silicon carbide epitaxy globally in terms of sales volume since 2023, with a market share exceeding 30% in 2024 [2]

瀚天天成电子科技(厦门)股份有限公司(简称：瀚天天成)于4月8日所递交的港股招股书满6个月，于10月8日失效，递表时中金公司（601995）为独家保荐 人。 招股书显示，瀚天天成是全球碳化硅(SiC)外延行业的领导者和革新者。根据灼识咨询的报告，自2023年来，按年销售片数计，瀚天天成是全球最大的碳化 硅外延供应商，2024年的市场份额超过30%。 ...

Group 1: New Listings and Filings - Five companies submitted applications for listing on the Hong Kong Stock Exchange from April 7 to April 13, 2023 [2] - Hantian Technology (Xiamen) Co., Ltd. is a global leader in the silicon carbide (SiC) epitaxy industry, with a projected market share exceeding 30% in 2024 [2] - IFBH Limited, a rapidly growing beverage and food company based in Thailand, has a market share of approximately 34% in the coconut water market in mainland China for 2024 [3] - Jihong Co., Ltd. focuses on cross-border social e-commerce and packaging solutions, ranking second in the B2C export e-commerce sector in China with a market share of 1.3% [3] - Jiangxi Biological Products Research Institute is the largest provider of human tetanus antitoxin in China, with a market share of 65.8% in 2024 [4] Group 2: Financial Performance - Hantian Technology's projected revenues for 2022, 2023, and 2024 are approximately RMB 441 million, RMB 1.143 billion, and RMB 974 million, respectively [2] - IFBH Limited's revenues for 2023 and 2024 are expected to be approximately RMB 87.44 million and about USD 158 million, with net profits of RMB 16.75 million and USD 33.32 million [3] - Jihong Co., Ltd. anticipates revenues of approximately RMB 5.376 billion, RMB 6.695 billion, and RMB 5.529 billion for 2022, 2023, and 2024, respectively [3] - Jiangxi Biological's projected revenues for 2022, 2023, and 2024 are approximately RMB 142 million, RMB 198 million, and RMB 221 million, respectively [4] - Ming Kee Hospital Group, the largest private hospital group in East China, expects revenues of approximately RMB 2.336 billion, RMB 2.688 billion, and RMB 2.659 billion for 2022, 2023, and 2024 [5] Group 3: Upcoming IPOs - Zhengli New Energy plans to offer 121.5 million H-shares at an IPO price of HKD 8.27, with net proceeds of HKD 928 million [5] - Ying'en Biotechnology-B is set to offer 15.0716 million shares with a price range of HKD 94.6 to HKD 103.2, expected to start trading on April 15, 2025 [6]